Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

Journal of Clinical Lipidology

Volumn 5, Issue 5, 2011, Pages 338-367

  Davidson, Michael H ^g   Ballantyne, Christie M ^a   Jacobson, Terry A ^j   Bittner, Vera A ^b   Braun, Lynne T ^c   Brown, Alan S ^d   Brown, W Virgil ^e   Cromwell, William C ^f   Goldberg, Ronald B ⁱ   McKenney, James M ^k   Remaley, Alan T ^l   Sniderman, Allan D ^m   Toth, Peter P ⁿ   Tsimikas, Sotirios ^o   Ziajka, Paul E ^p   Maki, Kevin C ^h   Dicklin, Mary R ^h  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c RUSH UNIVERSITY   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Lipoprotein and Metabolic Disorders Institute   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h Provident Clinical Research   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j EMORY UNIVERSITY   (United States)

^k VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^l NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^m MCGILL UNIVERSITY   (Canada)

ⁿ UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p Florida Lipid Institute   (United States)

more..

Author keywords

Apolipoprotein B; C reactive protein; Lipoprotein subfractions; Lipoprotein(a); Lipoprotein associated phospholipase A2; Low density lipoprotein particle concentration

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; DARAPLADIB; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SERUM AMYLOID A; SIMVASTATIN;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CONGENITAL HEART DISEASE; CORONARY ARTERY DISEASE; DRUG FATALITY; DRUG MEGADOSE; ENZYME ASSAY; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; STROKE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 80053914425     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.07.005     Document Type: Article

References (236)

1. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Arch Intern Med 148 1988 36 69
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report Circulation 106 2002 3143 3421
3. J.G. Robinson, S. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk J Am Coll Cardiol 53 2009 316 322
4. M.H. Davidson, K.C. Maki, and T.A. Pearson Results of the National Cholesterol Education Program (NCEP) evaluation project utilizing novel E-technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations Am J Cardiol 96 2005 556 563 (Pubitemid 41132774)
5. S.S. Virani, L.D. Woodard, and C.R. Landrum Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines Am Heart J 161 2011 1140 1146
6. M.J. Blaha, R.S. Blumenthal, E.A. Brinton, T.A. Jacobson, and National Lipid Association Taskforce on Non-HDL Cholesterol The importance of non-HDL cholesterol reporting in lipid management J Clin Lipidol 2 2008 267 273
7. H. Drexel, S. Aczel, T. Marte, A. Vonbank, and C.H. Saely Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis Atherosclerosis 208 2010 484 489
8. R.S. Rosenson, M.H. Davidson, and R. Pourfarzib Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk Atherosclerosis 213 2010 1 7
9. P.M. Ridker, E. Danielson, and F.A. Fonseca JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 259 2008 2195 2207
10. G.J. Blake, P.M. Ridker, and K.M. Kuntz Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia Am J Med 114 2003 485 494 (Pubitemid 36515111)
11. L.M. Biasucci, G. Biasillo, and A. Stefanelli Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance Clin Chem Lab Med 48 2010 1685 1691
12. T.A. Pearson, G.A. Mensah, and R.W. Alexander Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511 (Pubitemid 36158056)
13. PLAC® Enzyme Immunoassay for the Quantitative Determination ofLp-PLA2 in Human Plasma and Serum product insert information (diaDexus, Inc. South San Francisco, CA). Available at http://www.framinghamheartstudy.org/share/ protocols/lppla2m1-7s-protocol.pdf. Accessed May 16, 2011.
14. J.H. Contois, J.P. McConnell, and A.A. Sethi Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clin Chem 55 2009 407 419
15. S. Mora, M. Szklo, and J.D. Otvos LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis 192 2007 211 217 (Pubitemid 46602300)
16. J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, and D.C. Goff Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle numbers J Clin Lipidol 5 2011 105 113
17. B.G. Nordestgaard, M.J. Chapman, and K. Ray European Atherosclerosis Society Consensus Panel Lipoprotein (a) as a Cardiovascular Risk Factor Eur Heart J 31 2010 2844 2853
18. P.M. Ridker Clinical application of C-reactive protein for cardiovascular disease detection and prevention Circulation 107 2003 363 369 (Pubitemid 36158034)
19. P.M. Ridker, S.S. Bassuk, and P.P. Toth C-reactive protein and risk of cardiovascular disease: evidence and clinical application Curr Atheroscler Rep 5 2003 341 349 (Pubitemid 38898892)
20. T.A. Pearson, G.A. Mensah, and R.W. Alexander Centers for Disease Control and Prevention; American Heart Association: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511 (Pubitemid 36158056)
21. P.M. Ridker, C.H. Hennekens, J.E. Buring, and N. Rifai C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843 (Pubitemid 30165206)
22. P.M. Ridker, N. Rifai, and M.A. Pfeffer Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators Circulation 98 1998 839 844 (Pubitemid 28397432)
23. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease Circulation 97 1998 425 428 (Pubitemid 28090212)
24. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979 Erratum appears in N Engl J Med. 1997;337:356 (Pubitemid 27152782)
25. W. Koenig, M. Sund, and M. Fröhlich C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992 Circulation 99 1999 237 242 (Pubitemid 29056365)
26. L.H. Kuller, R.P. Tracy, J. Shaten, and E.N. Meilahn Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial Am J Epidemiol 144 1996 537 547 (Pubitemid 26304398)
27. R.P. Tracy, R.N. Lemaitre, and B.M. Psaty Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project Arterioscler Thromb Vasc Biol 17 1997 1121 1127 (Pubitemid 27260332)
28. M. Roivainen, M. Viik-Kajander, and T. Palosuo Infections, inflammation, and the risk of coronary heart disease Circulation 101 2000 252 257 (Pubitemid 30054151)
29. T.B. Harris, L. Ferrucci, and R.P. Tracy Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly Am J Med 106 1999 506 512 (Pubitemid 29231100)
30. M.A. Mendall, D.P. Strachan, and B.K. Butland C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men Eur Heart J 21 2000 1584 1590
31. Emerging Risk Factors Collaboration S. Kaptoge, E. Di Angelantonio, and G. Lowe C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet 375 2010 132 140
32. G. Liuzzo, L.M. Biasucci, and J.R. Gallimore The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina N Engl J Med 331 1994 417 424 (Pubitemid 24247397)
33. D.A. Morrow, N. Rifai, and E.M. Antman C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction J Am Coll Cardiol 31 1998 1460 1465 (Pubitemid 28273285)
34. L.M. Biasucci, G. Liuzzo, and R.L. Grillo Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability Circulation 99 1999 855 860 (Pubitemid 29094296)
35. H. Toss, B. Lindahl, A. Siegbahn, L. Wallentin, and Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group Fragmin during Instability in Coronary Artery Disease Circulation 96 1997 4204 4210
36. B. Lindahl, H. Toss, A. Siegbahn, P. Venge, L. Wallentin, and Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group Fragmin during Instability in Coronary Artery Disease N Engl J Med 343 2000 1139 1147
37. M.S. Sabatine, and D.A. Morrow PEACE Investigators Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease Circulation 115 2007 1528 1536 (Pubitemid 46648637)
38. F. Haverkate, S.G. Thompson, S.D. Pyke, J.R. Gallimore, and M.B. Pepys Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group Lancet 349 1997 462 466 (Pubitemid 27077826)
39. P.M. Ridker, and N. Cook Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores Circulation 109 2004 1955 1959 (Pubitemid 38544485)
40. M.K. Chang, C.J. Binder, M. Torzewski, and J.L. Witztum C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids Proc Natl Acad Sci U S A 99 2002 13043 13048
41. H.H. Shih, S. Zhang, W. Cao, A. Hahn, J. Wang, J.E. Paulsen, and D.C. Harnish CRP is a novel ligand for the oxidized LDL receptor LOX-1 Am J Physiol Heart Circ Physiol 296 2009 H1643 H1650
42. K. Yasojima, C. Schwab, E.G. McGeer, and P.L. McGeer Generation of C-reactive protein and complement components in atherosclerotic plaques Am J Pathol 158 2001 1039 1051 (Pubitemid 32221796)
43. S.K. Venugopal, S. Devaraj, I. Yuhanna, P. Shaul, and I. Jialal Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells Circulation 106 2002 1439 1441
44. S. Verma, C.H. Wang, and S.H. Li A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis Circulation 106 2002 913 919 (Pubitemid 34925323)
45. S. Fichtlscherer, G. Rosenberger, D.H. Walter, S. Breuer, S. Dimmeler, and A.M. Zeiher Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease Circulation 102 2000 1000 1006 (Pubitemid 30657516)
46. S. Devaraj, D.Y. Xu, and I. Jialal C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis Circulation 107 2003 398 404
47. S. Verma, S.H. Li, and M.V. Badiwala Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein Circulation 105 2002 1890 1896 (Pubitemid 34437614)
48. T.F. Luscher, and M. Barton Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs Circulation 102 2000 2434 2440
49. V. Pasceri, J.S. Cheng, J.T. Willerson, and E.T. Yeh Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs Circulation 103 2001 2531 2534 (Pubitemid 32521959)
50. S. Bhakdi, M. Torzewski, M. Klouche, and M. Hemmes Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation Arterioscler Thromb Vasc Biol 19 1999 2348 2354 (Pubitemid 29477835)
51. J. Torzewski, M. Torzewski, and D.E. Bowyer C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries Arterioscler Thromb Vasc Biol 18 1998 1386 1392 (Pubitemid 28421875)
52. T.P. Zwaka, V. Hombach, and J. Torzewski C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis Circulation 103 2001 1194 1197 (Pubitemid 32221339)
53. C.H. Wang, S.H. Li, and R.D. Weisel C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle Circulation 107 2003 1783 1790 (Pubitemid 36418360)
54. P.M. Ridker, E. Danielson, and F.A. Fonseca JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
55. W. Koenig, and P.M. Ridker Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities Eur Heart J 32 2011 75 83
56. E.Y. Yang, V. Nambi, and Z. Tang Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study J Am Coll Cardiol 54 2009 2388 2395
57. P.M. Ridker, N. Rifai, and M. Clearfield Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965 (Pubitemid 32568149)
58. P.M. Ridker, N.P. Paynter, N. Rifai, J.M. Gaziano, and N.R. Cook C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men Circulation 118 2008 2243 2251
59. P.M. Ridker, J.E. Buring, N. Rifai, and N.R. Cook Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score JAMA 297 2007 611 619
60. M. Cushman, C. Legault, and E. Barrett-Connor Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study Circulation 100 1999 17 22
61. P.M. Ridker The JUPITER trial: results, controversies, and implications for prevention Circ Cardiovasc Qual Outcomes 2 2009 279 285
62. P.M. Ridker, E. Danielson, and F.A. Fonseca JUPITER Trial Study Group Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
63. S. Ahmed, C.P. Cannon, S.A. Murphy, and E. Braunwald Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial Eur Heart J 27 2006 2323 2329 (Pubitemid 44453576)
64. D.A. Morrow, J.A. de Lemos, and M.S. Sabatine Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial Circulation 114 2006 281 288 (Pubitemid 44297094)
65. S.E. Nissen Aggressive lipid-lowering therapy and regression of coronary atheroma - reply JAMA 292 2004 39 40
66. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N Engl J Med 352 2005 29 38 (Pubitemid 40075678)
67. S. Mora, and P.M. Ridker Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 97 2A 2006 33A 341A
68. J. Shen, and J.M. Ordovas Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents Clin Chem 55 2009 256 264
69. L.M. Belalcazar, D.M. Reboussin, and S.M. Haffner Look AHEAD Research Group A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study Diabetes Care 33 2010 2297 2303
70. Y. Horiuchi, S. Hirayama, and S. Soda Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels J Atheroscler Thromb 17 2010 722 729
71. P.P. Toth, P.A. McCullough, M.S. Wegner, and K.J. Colley Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker Exp Rev Cardiovasc Ther 8 2010 425 438
72. L.T. Braun, and M.H. Davidson Lp-PLA2: a new target for statin therapy Curr Atheroscler Rep 12 2010 29 33
73. 2: an independent predictor of coronary artery disease events in primary and secondary prevention Am J Cardiol 101 2008 23F 33F
74. 2, high-sensitivity C-reactive protein, and risk for incident heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study Circulation 109 2004 837 842 (Pubitemid 38252734)
75. C.M. Ballantyne, R.C. Hoogeveen, and H. Bang Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study Arch Intern Med 165 2005 2479 2484 (Pubitemid 41720009)
76. E. Shahar, L.E. Chambless, and W.D. Rosamond Atherosclerosis Risk in Communities Study Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study Stroke 34 2003 623 631 (Pubitemid 36307382)
77. P.B. Gorelick Lipoprotein-associated phospholipase A2 and risk of stroke Am J Cardiol 101 12A 2008 34F 40F
78. Lp-PLA(2) Studies Collaboration A. Thompson, P. Gao, L. Orfei, S. Watson, E. Di Angelantonio, S. Kaptoge, C. Ballantyne, C.P. Cannon, M. Criqui, M. Cushman, A. Hofman, C. Packard, S.G. Thompson, R. Collins, and J. Danesh Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 2010 1536 1544
79. W. Koenig, D. Twardella, H. Brenner, and D. Rothenbacher Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress Arterioscler Thromb Vasc Biol 26 2006 1586 1593 (Pubitemid 44288987)
80. T. Häkkinen, J.S. Luoma, and M.O. Hiltunen Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions Arterioscler Thromb Vasc Biol 19 1999 2909 2917 (Pubitemid 30029817)
81. 2: an independent predictor of coronary artery disease events in primary and secondary prevention Am J Cardiol 101 12A 2008 23F 33F
82. M.A. Corson, P.H. Jones, and M.H. Davidson Review of the evidence for the clinical utility of lipoprotein-associated A2 as a cardiovascular risk marker Am J Cardiol 101 12A 2008 41F 450F
83. A. Lerman, and J.P. McConnell Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Am J Cardiol 101 12A 2008 11F 122F
84. C.H. Macphee, K.E. Moores, and H.F. Boyd Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor Biochem J 338 Pt 2 1999 479 487
85. S. Lavi, J.P. McConnell, C.S. Rihal, A. Prasad, V. Mathew, L.O. Lerman, and A. Lerman Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans Circulation 115 2007 2715 2721 (Pubitemid 46842787)
86. J. Herrmann, D. Mannheim, and C. Wohlert Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome Eur Heart J 30 2009 2930 2938
87. R.L. Wilensky, Y. Shi, and E.R. Mohler 3rd Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development Nat Med 14 2008 1059 1066
88. H.M. Garcia-Garcia, and P.W. Serruys Phospholipase A2 inhibitors Curr Opin Lipidol 20 2009 327 332
89. M.H. Davidson, M.A. Corson, and M.J. Alberts Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines Am J Cardiol 101 12A 2008 51F 57F
90. 2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial Circulation 113 2006 1745 1752 (Pubitemid 43958467)
91. 2 activity and mass in relation to vascular disease and nonvascular mortality J Intern Med 268 2010 348 358
92. M.H. Davidson Clinical significance of statin pleiotropic effects: hypotheses versus evidence Circulation 111 2005 2280 2281 (Pubitemid 40647061)
93. E.J. Schaefer, J.R. McNamara, and B.F. Asztalos Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects Am J Cardiol 95 2005 1025 1032 (Pubitemid 40544302)
94. J.B. Muhlestein, H.T. May, and J.R. Jensen The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia. the DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study J Am Coll Cardiol 48 2006 396 401
95. V.G. Saougos, A.P. Tambaki, and M. Kalogirou Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2 Arterioscler Thromb Vasc Biol 27 2007 2236 2243 (Pubitemid 350287255)
96. T. Tzotzas, T.D. Filippatos, A. Triantos, E. Bruckert, A.D. Tselepis, and D.N. Kiortsis Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women Nutr Metab Cardiovasc Dis 18 2008 477 482
97. E.R. Mohler 3rd, C.M. Ballantyne, and M.H. Davidson Darapladib Investigators The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.J Am Coll Cardiol 51 2008 1632 1641 (Pubitemid 351635837)
98. R.L. Wilensky, Y. Shi, and E.R. Mohler 3rd Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development Nat Med 14 2008 1059 1066
99. P.W. Serruys, H.M. García-García, and P. Buszman Integrated Biomarker and Imaging Study-2 Investigators Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque Circulation 118 2008 1172 1182
100. H. White, C. Held, and R. Stewart Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease Am Heart J 160 2010 655 661
101. E. Ingelsson, E.J. Schaefer, and J.H. Contois Clinical utility of different lipid measures for prediction of coronary heart disease in men and women JAMA 298 2007 776 785 (Pubitemid 47263160)
102. I. Shai, E.B. Rimm, and S.E. Hankinson Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines Circulation 110 2004 2824 2830 (Pubitemid 39473604)
103. S. Mora, J.D. Otvos, N. Rifai, R.S. Rosenson, J.E. Buring, and P.M. Ridker Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 119 2009 931 939
104. M. Benn, B.G. Nordestgaard, G.B. Jensen, and A. Tybjaerg-Hansen Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study Arterioscler Thromb Vasc Biol 27 2007 661 670
105. P.M. Ridker, N. Rifai, N.R. Cook, G. Bradwin, and J.E. Buring Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women JAMA 294 2005 326 333 (Pubitemid 41043776)
106. R. Jiang, M.B. Schulze, T. Li, N. Rifai, M.J. Stampfer, E.B. Rimm, and F.B. Hu Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes Diabetes Care 27 2004 1991 1997 (Pubitemid 38989244)
107. T. Pischon, C.J. Girman, F.M. Sacks, N. Rifai, M.J. Stampfer, and E.B. Rimm Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men Circulation 112 2005 3375 3383 (Pubitemid 43739551)
108. G. Bruno, F. Merletti, and A. Biggeri Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study Diabetologia 49 2006 937 944
109. K.L. Chien, H.C. Hsu, T.C. Su, M.F. Chen, Y.T. Lee, and F.B. Hu Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese J Lipid Res 48 2007 2499 2505 (Pubitemid 350058761)
110. I. Holme, A.H. Aastveit, I. Jungner, and G. Walldius Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtalityRISk study (AMORIS) J Intern Med 264 2008 30 38 (Pubitemid 351813479)
111. M.J. McQueen, S. Hawken, and X. Wang INTERHEART study investigators Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study Lancet 372 2008 224 233 (Pubitemid 351978112)
112. S. Parish, R. Peto, A. Palmer International Studies of Infarct Survival Collaborators The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls Eur Heart J 30 2009 2137 2146
113. P.J. Talmud, E. Hawe, G.J. Miller, and S.T. Humphries Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men Arterioscler Thromb Vasc Biol 22 2002 1918 1923 (Pubitemid 35315782)
114. A.D. Sniderman, J. de Graaf, and P. Couture ApoB and the atherogenic ApoB dyslipoproteinemias P.O. Kwiterovich Jr. The Johns Hopkins Textbook of dyslipidemia 2009 Lippincott Williams & Wilkins Philadelphia, PA 196 210
115. D.J. Blom, F.H. O'Neill, and A.D. Marais Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations Clin Chem 51 2005 904 907 (Pubitemid 40577931)
116. A. Sniderman, A. Tremblay, J. Bergeron, C. Gagné, and P. Couture Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B J Clin Lipidol 1 2007 256 263 (Pubitemid 47370863)
117. R.M. Krauss, and D.J. Burke Identification of multiple subclasses of plasma low density lipoproteins in normal humans J Lipid Res 23 1982 97 104 (Pubitemid 12112617)
118. A.D. Sniderman, T. Scantlebury, and K. Cianflone Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus Ann Intern Med 135 2001 447 459 (Pubitemid 32845869)
119. B. Lamarche, I. Lemieux, and J.P. Després The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects Diabetes Metab 25 1999 199 211 (Pubitemid 29426371)
120. R.M. Krauss, and P.W. Siri Metabolic abnormalities: triglyceride and low-density lipoprotein Endocrinol Metab Clin North Am 33 2004 405 415 (Pubitemid 38680637)
121. J. Genest Jr., J.M. Bard, J.C. Fruchart, J.M. Ordovas, and E.J. Schaefer Familial hypoalphalipoproteinemia in premature coronary artery disease Arterioscler Thromb 13 1993 1728 1737
122. A.D. Sniderman, G.R. Dagenais, B. Cantin, J.P. Després, and B. Lamarche High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol Am J Cardiol 87 2001 792 793 (Pubitemid 32209103)
123. A.D. Sniderman, M. Castro Cabezas, and J. Ribalta A proposal to redefine familial combined hyperlipidaemia - third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during scientific sessions of the European Society for Clinical Investigation Eur J Clin Invest 32 2002 71 73 (Pubitemid 36232725)
124. M.J. Veerkamp, J. de Graaf, J.C. Hendriks, P.N. Demacker, and A.F. Stalenhoef Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study Circulation 109 2004 2980 2985 (Pubitemid 38808320)
125. A. Sniderman, P. Couture, and J. deGraaf Diagnosis and treatment of apolipoprotein B dyslipoproteinemias Nat Rev Endocrinol 6 2010 335 346
126. J. Liu, C.T. Sempos, R.P. Donahue, J. Dorn, M. Trevisan, and S.M. Grundy Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease Am J Cardiol 98 2006 1363 1368 (Pubitemid 44666646)
127. Emerging Risk Factors Collaboration E. Di Angelantonio, N. Sarwar, and P. Perry Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
128. A.D. Sniderman, K. Williams, and J.H. Contois A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
129. J.H. Contois, J.P. McConnell, and A.A. Sethi AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clin Chem 55 2009 407 419
130. J.H. Contois, G.R. Warnick, and A.D. Sniderman Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B measurement J Clin Lipidol 5 2011 264 272
131. S.M. Marcovina, J.J. Albers, H. Kennedy, J.V. Mei, L.O. Henderson, and W.H. Hannon International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material Clin Chem 40 1994 586 592
132. J. Elovson, J.E. Chatterton, and G.T. Bell Plasma very low density lipoproteins contain a single molecule of apolipoprotein B J Lipid Res 29 1988 1461 1473 (Pubitemid 19013040)
133. J.P. Kane Apolipoprotein B: structural and metabolic heterogeneity Annu Rev Physiol 45 1983 637 650
134. A. Langsted, and B.G. Nordestgaard Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58,434 individuals from the Copenhagen General Population Study Clin Chem 57 2011 482 489
135. E.B. Smith, and E.M. Staples Intimal and medial plasma protein concentrations and endothelial function Atherosclerosis 41 1982 295 308 (Pubitemid 12213360)
136. W.G. Miller, G.L. Myers, and I. Sakurabayashi Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures Clin Chem 56 2010 977 986
137. J. Genest, R. McPherson, and J. Frohlich 2009 Canadian Cardiovascular Society/Canadian Guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
138. S.M. Grundy, J.I. Cleeman, and C.N. Merz Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
139. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
140. F. Wiesbauer, H. Blessberger, and D. Azar Familial-combined hyperlipidaemia in very young myocardial infarction survivors (
141. R. Hayward, T.P. Hofer, and S. Vijan Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem Ann Intern Med 145 2006 520 530 (Pubitemid 46780956)
142. A.M. Gotto Jr., E. Whitney, and E.A. Stein Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation 101 2000 477 484 (Pubitemid 30080860)
143. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington CARDS Investigators Primary preventions of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696 (Pubitemid 39140624)
144. J.C. LaRosa, S.M. Grundy, and D.D. Waters Treating to New Targets (TNT) Investigators intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435 (Pubitemid 40471450)
145. P.M. Ridker, E. Danielson, and F.A.H. Fonseca JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
146. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
147. K.K. Ray, C.P. Cannon, R. Cairns, D.A. Morrow, P.M. Ridker, and E. Braunwald Prognostic utility of Apo B/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT TIMI 22 Arterioscler Thromb Vasc Biol 29 2009 424 430
148. J.E. Roeters van Lennep, H.T. Westerveld, H.W.O. Roeters van Lennep, A.H. Zwinderman, W. Erkelens, and E.E. van der Wall Apolipoprotein concentrations during treatment and recurrent coronary artery disease events Arterioscler Thromb Vasc Biol 20 2000 2408 2413
149. J.J. Kastelein, W.A. van der Steeg, and I. Holme TNT Study Group, IDEAL Study Group Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
150. R.J. Simes, I.C. Marschner, and D. Hunt LIPID Study Investigators Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105 2002 1162 1169 (Pubitemid 34225815)
151. J. Shepherd, G.J. Blauw, and M.B. Murphy PROSPER study group, PROspective Study of Pravastatin in the Elderly at Risk Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630 (Pubitemid 35379733)
152. A.D. Sniderman Differential response of cholesterol particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice J Clin Lipidol 2 2008 36 42 (Pubitemid 351250867)
153. E.A. Stein, A. Sniderman, and P. Laskarzewski Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B Am J Cardiol 96 2005 36K 43K (Pubitemid 41598111)
154. J.D. Brunzell, M. Davidson, and C.D. Furberg American Diabetes Association American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 31 2008 811 822
155. S.M. Grundy Low-density lipoprotein, non-high density lipoprotein and apolipoprotein B as targets of lipid-lowering therapy Circulation 106 2002 2526 2529 (Pubitemid 35340685)
156. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
157. J.R. Downs, M. Clearfield, and S. Weis AFCAPS/TexCAPS Research Group Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622 (Pubitemid 28248586)
158. T.R. Pedersen, O. Faergeman, and J.J.P. Kastelein Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial JAMA 294 2005 2437 2445 (Pubitemid 41627921)
159. C.P. Cannon, E. Braunwald, and C.H. McCabe Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504 (Pubitemid 38477774)
160. T.A. Jacobson Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk Mayo Clin Proc 86 2011 762 780
161. J.G. Robinson, B. Smith, N. Maheshwari, and H. Schrott Pleiotropic effects of statins: benefit beyond cholesterol reduction? J Am Coll Cardiol 46 2005 1855 1862 (Pubitemid 41579807)
162. J.G. Robinson, S. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density cholesterol reduction and coronary heart disease risk J Am Coll Cardiol 53 2009 316 322
163. V. Ramjee, L.S. Sperling, and T.A. Jacobson Non-HDL versus Apo B in cardiovascularrisk stratification: do the math J Am Coll Cardiol 58 2011 457 463
164. S.S. Virani, L.D. Woodard, and C.R. Landrum Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines Am Heart J 161 2011 1140 1146
165. J.D. Otvos, E.J. Jeyarajah, and W.C. Cromwell Measurement issues related to lipoprotein heterogeneity Am J Cardiol 90 2002 22i 29i (Pubitemid 35284908)
166. W.C. Cromwell, and J.D. Otvos Low-density lipoprotein particle number and risk for cardiovascular disease Curr Atheroscler Rep 6 2004 381 387 (Pubitemid 39359480)
167. W.C. Cromwell, J.D. Otvos, and M.J. Keyes LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - Implications for LDL management J Clin Lipidol 1 2007 583 592 (Pubitemid 350215511)
168. A.D. Sniderman, C.D. Furberg, and A. Keech Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment Lancet 361 2003 777 780 (Pubitemid 36293636)
169. A.D. Sniderman Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice J Clin Lipidol 2 2008 36 42 (Pubitemid 351250867)
170. W.C. Cromwell, and T.A. Barringer Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease Curr Cardiol Rep 11 2009 468 475
171. S. Kathiresan, J.D. Otvos, and L.M. Sullivan Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study Circulation 113 2006 20 29 (Pubitemid 43958484)
172. W.C. Cromwell, and J.D. Otvos Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dL Am J Cardiol 98 2006 1599 1602 (Pubitemid 44827965)
173. J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, and D.C. Goff Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
174. J. Otvos, W. Cromwell, and I. Shalaurova LDL particles, but not LDL cholesterol, are highly elevated in the metabolic syndrome - Results from the Framingham Offspring Study Circulation 108 2003 IV-740
175. W.T. Garvey, S. Kwon, and D. Zheng Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance Diabetes 52 2003 453 462 (Pubitemid 36173203)
176. P. Glasziou, L. Irwig, and J.J. Deeks When should a new test become the current reference standard? Ann Intern Med 149 2008 816 821
177. P. Greenland, J.S. Alpert, and G.A. Beller American College of Cardiology Foundation, American Heart Association 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 56 2010 e50 e103
178. L.B. Nielsen Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis Atherosclerosis 123 1996 1 15 (Pubitemid 26175065)
179. J.H.D.J. Rudd, and P.L. Weissberg Atherosclerotic biology and epidemiology of disease R. Topol, Textbook of Cardiovascular Medicine 2002 Lippincott, Williams & Wilkins Philadelphia, PA 2 12
180. B.G. Nordestgaard, R. Wootton, and B. Lewis Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media Arterioscler Thromb Vasc Biol 15 1995 534 542
181. I. Tabas, K.J. Williams, and J. Borén Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 2007 1832 1844 (Pubitemid 350287108)
182. A.D. Sniderman, and M. Castro Cabezas A proposal to redefine familial combined hyperlipidaemia - third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation Eur J Clin Invest 32 2002 71 73 (Pubitemid 36232725)
183. A. Gaddi, A.F. Cicero, F.O. Odoo, A.A. Poli, R. Paoletti, and Atherosclerosis and Metabolic Diseases Study Group Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date Vasc Health Risk Manag 3 2007 877 886
184. R.S. Rosenson, J.D. Otvos, and D.S. Freedman Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial Am J Cardiol 90 2002 89 94 (Pubitemid 34775113)
185. J.D. Otvos, D. Collins, and D.S. Freedman Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation 113 2006 1556 1563 (Pubitemid 43739414)
186. J.H. Contois, J.P. McConnell, and A.A. Sethi AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clin Chem 55 2009 407 419
187. W.C. Cromwell, H.E. Bays, and P.P. Toth Lipoprotein subfraction analysis using nuclear magnetic resonance spectroscopy J.E. Adams, F. Apple, A.S. Jaffe, Markers in Cardiology: A Case-Oriented Approach 2007 Blackstone London 217 250
188. Emerging Risk Factors Collaboration S. Erqou, S. Kaptoge, and P.L. Perry Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 2009 412 423
189. J. Danesh, R. Collins, and R. Peto Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies Circulation 102 2000 1082 1085
190. A. Bennet, E. Di Angelantonio, and S. Erqou Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data Arch Intern Med 168 2008 598 608 (Pubitemid 351468395)
191. B.G. Nordestgaard, M.J. Chapman, and K. Ray European Atherosclerosis Society Consensus Panel Lipoprotein (a) as a cardiovascular risk factor Eur Heart J 31 2010 2844 2853
192. P.R. Kamstrup, A. Tybjærg-Hansen, R. Steffensen, and B.G. Nordestgaard Geneticallyelevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
193. D.J. Rader, W. Cain, and K. Ikewaki The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate J Clin Invest 93 1994 2758 2763
194. M.L. Koschinsky, and S.M. Marcovina Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity Curr Opin Lipidol 15 2004 167 174 (Pubitemid 38453403)
195. F. Kronenberg, M.F. Kronenberg, and S. Kiechl Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study Circulation 100 1999 1154 1160 (Pubitemid 29426589)
196. S.N. Sotiriou, V.V. Orlova, and N. Al-Fakhri Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin FASEB J 20 2006 559 561 (Pubitemid 46671249)
197. S. Kiechl, J. Willeit, M. Mayr, B. Viehweider, M. Oberhollenzer, F. Kronenberg, C.J. Wiedermann, S. Oberthaler, Q. Xu, J.L. Witzum, and S. Tsimikas Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: Prospective results from the Bruneck study Arterioscler Thromb Vasc Biol 27 2007 1788 1795 (Pubitemid 47207175)
198. C. Bergmark, A. Dewan, A. Orsoni, E. Merki, E.R. Miller, M.J. Shin, C.J. Binder, S. Horkko, R.M. Krauss, M.J. Chapman, J.L. Witztyn, and S. Tsimikas A novel function of lipoprotein (a) as a preferential carrier of oxidized phospholipids in human plasma J Lipid Res 49 2008 2230 2239
199. S. Tsimikas, Z. Mallat, P.J. Talmud, J.J. Kastelein, N.J. Wareham, M.S. Sandhu, E.R. Miller, J. Benessiano, A. Tedgui, J.L. Qitzum, K.T. Khaw, and S.M. Boekholdt Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events J Am Coll Cardiol 56 2010 946 955
200. D. Rouy, P. Grailhe, F. Nigon, J. Chapman, and E. Anglés-Cano Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu Arterioscler Thromb 11 1991 629 638
201. N.W. Boonmark, X.J. Lou, and Z.J. Yang Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice J Clin Invest 100 1997 558 564 (Pubitemid 27340502)
202. G. Utermann Lipoprotein(a) C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, The Metabolic and Molecular Bases of Inherited Disease 8th ed. 2001 McGraw-Hill New York, NY 2753 2787
203. G.D. Smith, and S. Ebrahim Mendelian randomization: prospects, potentials, and limitations Int J Epidemiol 33 2004 30 42 (Pubitemid 38528650)
204. M. Koschinsky, and S.M. Marcovina Lipoprotein(a) C. Ballantyne, Clinical Lipidology: A Companion to Braunwauld's Heart Disease 2009 Saunders Elsevier Philadelphia, PA 130 143
205. J. Suk Danik Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events J Am Coll Cardiol 52 2008 124 131 (Pubitemid 351885446)
206. K. Tziomalos, V.G. Athyros, A.S. Wierzbicki, and D.P. Mikhailidis Lipoprotein a: where are we now? Curr Opin Cardiol 24 2009 351 357
207. Brown WV, C.M. Ballantyne, Jones PH, and S. Marcovina Management of Lp(a) J Clin Lipidol 4 2010 240 247
208. F.M. Sacks, and H. Campos Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal J Clin Endocrinol Metab 88 2003 4525 4532 (Pubitemid 37357487)
209. H.R. Superko Advanced lipoprotein testing and subfractionation are clinically useful Circulation 119 2009 2383 2395
210. S. Ip, A.H. Lichtenstein, M. Chung, J. Lau, and E.M. Balk Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes Ann Intern Med 150 2009 474 484
211. W. Ensign, N. Hill, and C.B. Heward Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics Clin Chem 52 2006 1722 1727 (Pubitemid 44330706)
212. M. Chung, A.H. Lichtenstein, S. Ip, J. Lau, and E.M. Balk Comparability of methods for LDL subfraction determination: a systematic review Atherosclerosis 205 2009 342 348
213. L.L. Rudel, J.S. Parks, F.L. Johnson, and J. Babiak Low density lipoproteins in atherosclerosis J Lipid Res 27 1986 465 474 (Pubitemid 16051145)
214. W. Patsch, R. Ostlund, I. Kuisk, R. Levy, and G. Schonfeld Characterization of lipoprotein in a kindred with familial hypercholesterolemia J Lipid Res 23 1982 1196 1205 (Pubitemid 13187617)
215. S. Mora, M. Szklo, and J.D. Otvos LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis 192 2007 211 217 (Pubitemid 46602300)
216. H. Campos, G.O. Roederer, S. Lussier-Cacan, J. Davignon, and R.M. Krauss Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease Arterioscler Thromb Vasc Biol 15 1995 1043 1048
217. H. Campos, L.A. Moye, S.P. Glasser, M.J. Stampfer, and F.M. Sacks Low-density lipoprotein size, pravastatin treatment, and coronary events JAMA 286 2001 1468 1474 (Pubitemid 33015503)
218. B. Lamarche, J.P. Després, S. Moorjani, B. Cantin, G.R. Dagenais, and P.J. Lupien Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study) Am J Cardiol 75 1995 1189 1195
219. J.D. Otvos, D. Collins, and D.S. Freedman Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation 113 2006 1556 1563 (Pubitemid 43739414)
220. L. Kuller, A. Arnold, and R. Tracy Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study Arterioscler Thromb Vasc Biol 22 2002 1175 1180 (Pubitemid 34764870)
221. G.J. Blake, J.D. Otvos, N. Rifai, and P.M. Ridker Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women Circulation 106 2002 1930 1937 (Pubitemid 35176297)
222. D.M. Hallman, S.A. Brown, C.M. Ballantyne, A.R. Sharrett, and E. Boerwinkle Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the Atherosclerosis Risk in Communities (ARIC) Study Biomarkers 9 2004 190 202 (Pubitemid 39255640)
223. R. Ross Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115 126 (Pubitemid 29054847)
224. P.T. Williams, R.M. Krauss, K.M. Vranizan, and P.D. Wood Changes in lipoprotein subfractions during diet-induced and exercise-induced weight loss in moderately overweight men Circulation 81 1990 1293 1304 (Pubitemid 20119628)
225. J. Vakkilainen, G. Steiner, and J.C. Ansquer DAIS Group Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS) Circulation 107 2003 1733 1737 (Pubitemid 36418352)
226. R.S. Rosenson, H.B. Brewer Jr., and M.J. Chapman HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events Clin Chem 57 2011 392 410
227. M.P. Reilly, and A.R. Tall HDL proteomics: pot of gold or Pandora's box? J Clin Invest 117 2007 595 598 (Pubitemid 46348516)
228. Emerging Risk Factors Collaboration E. Di Angelantonio, N. Sarwar, and Perry P Major lipids, apolipoproteins and risk of vascular disease JAMA 302 2009 1993 2000
229. C. Baigent, A. Keech, P.M. Kearney Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
230. P. Barter, A.M. Gotto, and J.C. LaRosa Treating to New Targets Investigators HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310 (Pubitemid 47481452)
231. P.M. Ridker, J. Genest, and S.M. Boekholdt JUPITER Trial Study Group HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2010 333 339
232. M. Briel, I. Ferreira-Gonzalez, and J.J. You Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ 338 2009 b92
233. J.D. Otvos, D. Collins, and D.S. Freedman Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation 113 2006 1556 1563 (Pubitemid 43739414)
234. P.T. Williams, and D.E. Feldman Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort Atherosclerosis 214 2011 196 202
235. B.F. Asztalos, S. Demissie, and L.A. Cupples LpA-I, LpA-I: A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial Atherosclerosis 188 2006 59 67 (Pubitemid 44142535)
236. P.S. Green, T. Vaisar, and S. Pennathur Combined statin and niacin therapy remodels the high-density lipoprotein proteome Circulation 118 2008 1259 1267